XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
   Pharmacotherapy
   Radiotherapy
   Vaccination
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Therapy Channel
subscribe to Therapy newsletter

Latest Research : Cancer : Therapy

   DISCUSS   |   EMAIL   |   PRINT
LErafAON-ETU : a Liposome Entrapped c-raf Antisense Oligonucleotide for Advanced Cancer
May 21, 2005, 10:42, Reviewed by: Dr.

"The emerging technology of the liposome formulation used for LErafAON-ETU in this study represents an opportunity for potentially improving the delivery of novel cancer therapies."

 
NeoPharm (Nasdaq:NEOL) announced that preliminary Phase I clinical trial data for the Company's NeoLipid(TM) compound LErafAON-ETU was published in the American Society for Clinical Oncology (ASCO) Annual Meeting Proceedings. ASCO was held May 13-17, 2005 in Orlando, Florida.

LErafAON-ETU - ASCO Meeting Proceedings - Abstract #3214

LErafAON-ETU is NeoPharm's easy-to-use liposomal formulation of an antisense oligonucleotide (AON) complementary to the c-raf mRNA sequence, which mediates tumor cell growth.

This drug formulation utilizes the Company's NeoPhectin(TM) transfection reagent which consists of a novel, positively charged, synthetic cardiolipin (PCL-2) and appears to eliminate the need for extensive phosphorothioate modification of the AON which can be associated with toxicity.

This reagent also has potential use in the delivery of nucleic acids and siRNA molecules.

"The emerging technology of the liposome formulation used for LErafAON-ETU in this study represents an opportunity for potentially improving the delivery of novel cancer therapies," stated Michael Gordon, MD, Associate Professor of Medicine - University of Arizona College of Medicine, Associate Director-Arizona Cancer Center-Greater Phoenix Area and the Investigator on the NeoPharm Phase I LErafAON-ETU Clinical Study.

The published abstract entitled, "Phase I Study of LErafAON-ETU, an Easy-To-Use Formulation of Liposome Entrapped c-raf Antisense Oligonucleotide, in Advanced Cancer Patients," highlights the successful initial clinical dosing of this novel drug formulation.

This Phase I dose-escalation study is designed to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of LErafAON-ETU in patients with advanced cancer. LErafAON-ETU is planned to be administered as an intravenous infusion once weekly for 3 consecutive weeks (a treatment cycle).

Patients are eligible to receive repeated treatment cycles until disease progression or unacceptable toxicity occurs. Dose levels of 7.5, 15, 30, 60, 120, 240, and 480 mg/m2 are planned, depending on the tolerability of LErafAON-ETU. Dose escalation is ongoing in this study.
 

- The Study was published in the American Society for Clinical Oncology (ASCO) Annual Meeting Proceedings. ASCO was held May 13-17, 2005 in Orlando, Florida.
 

www.neophrm.com

 
Subscribe to Therapy Newsletter
E-mail Address:

 

About NeoPharm, Inc.

NeoPharm, Inc., based in Lake Forest, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. The Company has a portfolio of cancer compounds in various stages of development. Additional information can be obtained by visiting NeoPharm's Website at www.neophrm.com.

Forward Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development program, including, but not limited to, LErafAON-ETU, progress and outcomes of clinical trials of the Company's drug product candidates, including LErafAON-ETU, financial projections, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug and non-drug compounds, including, but not limited to LErafAON-ETU, uncertainty regarding the ability of licensees of our drugs, to obtain necessary foreign drug approvals or to adequately develop foreign markets, uncertainty regarding the availability of third party production capacity, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug and non-drug compounds that could slow or prevent products coming to market, including, but not limited to, LErafAON-ETU, uncertainty regarding the Company's ability to market its drug and non-drug products directly or through independent distributors, including, but not limited to LErafAON-ETU, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to LErafAON-ETU, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual reports on Form 10-K and quarterly reports on Forms 10-Q. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results.

Contact NeoPharm Paul Arndt, 847-295-8678 Ext. 215 [email protected]


Related Therapy News

Genomic signatures to guide the use of chemotherapeutics
CDK2/FOXO1 as drug target to Prevent Tumors
Telomerase inhibitors may revolutionize cancer therapy
First ever shots of the cervical cancer vaccine administered in Queensland
Gleevec can be toxic to the heart
Anti-cancer possibilities seen for certain monoamine oxidase inhibitors
AS101 protects the testis from the effects of paclitaxel
Microbeam Radiation Therapy (MRT) Could Improve Cancer Treatment
Novel EGFR antibody mAb 806 targets tumors but not normal tissues
Oral chemotherapy option soon for cancer


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us